An overview of integration

Jiyang is a biomedical company in China, specializing in the development and production of new drugs for the treatment of cancer and autoimmune diseases and biological analogs. Through the efficient R & D system and the production capacity of low-cost products, the market has a high-volume and affordable new biological products, and develops a variety of treatment products. The waiting material management line of the collection currently includes 9 single clone antibody products, of which 3 are the core products in the III period. It has the capacity of internal research, pre-bed and bed development and production, and is building a sales facility to prepare for the commercialization of selected products. According to Frost Sullivan, the biological reactor system equipped with production facilities in Taizhou is one of the largest production facilities in China by production capacity.

According to Frost Sullivan's data, the market regulation of single clone antibodies is 118 billion yuan, accounting for 5.4 percent of China's biotech market in 2017, and is expected to increase to 69.6 billion yuan in 2022. The complex annual growth rate from 2017 to 2022 is 42.6%. According to Frost Sullivan, cancer and autoimmune diseases are one of the largest areas of treatment in the Mono-Clone Antibody Division, with a total of 104 billion yuan in 2017 and 64.6 billion yuan in 2022.

Negative factor

Since its establishment, the market has not generated revenue and accumulated significant revenue, and it is expected that it will continue to generate revenue after the collection date, and may not be able to achieve or maintain profits. If the collector fails to successfully complete the development of the bed, the approval of the supervision and the commercialization of the candidate materials of the collection, or if such matters encounter significant delays, the investors may lose all or part of their investment.